Effects of Flupentixol-Melitracen as an add-on therapy in functional Dyspepsia patient who already recieve PPI and prokinetics Functional dyspepsia Flupentixol-Melitracen Overall symptom relief Quality of life
Conditions
Interventions
dose: 0.5 mg of Flupentixol and 10 mg of Melitracen as fixed drug combination
duration: 2 weeks
mode of administration: oral daily dose
Flupentixol-Melitracen
Sponsors
Faculty of medicine, Khon Kaen university
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 70 years. 2. Diagnosed with functional dyspepsia according to the Rome IV diagnostic criteria, without alarm features. Participants must also have: - Normal upper gastrointestinal endoscopy findings, and - No evidence of Helicobacter pylori infection within 1 year prior to enrollment in the study. 3. Patients who continue to experience symptoms despite receiving treatment with a proton pump inhibitor (PPI) and prokinetic agents for at least 8 weeks prior to enrollment in the study. 4. Able to read, write, and communicate in Thai. 5. Normal findings on physical examination.
Exclusion criteria
Exclusion criteria: 1. History of hypersensitivity or contraindication to flupentixol-melitracen 2. History of using nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, or anticoagulant medications within 1 month prior to enrollment in the study 3. Presence of symptoms suggestive of gastroesophageal reflux disease (GERD) or irritable bowel syndrome (IBS) that may interfere with establishing a clear diagnosis 4. Pregnant or breastfeeding women 5. History of cardiovascular diseases, including cardiac arrhythmia or myocardial ischemia, within 3 months prior to enrollment in the study 6. Presence of other severe comorbid conditions, such as end-stage renal disease, end-stage liver cirrhosis, malignancy, or other serious illnesses 7. Use of anxiolytics or antidepressant medications within 3 months prior to enrollment in the study or current use of such medications 8. Patients with untreated narrow-angle glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall symptom relief at 2 weeks after the intervention subjective question | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional dyspepsia symptoms assessment at 2 weeks after the intervention GOS questionnare,Quality of life assessment at 2 weeks after the intervention SF-NDI questionnare | — |
Countries
Thailand
Contacts
Public ContactChalida Krataithong
Khon Kaen university
Outcome results
None listed